Supplementary Figures 1 - 6 from Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 1469K, Different ABL TKIs demonstrate potency differences in relative cellular and biochemical target inhibition (S1); Incomplete restoration of BCR-ABL signaling activity following washout of dasatinib or ponatinib tracks with intracellular drug retention and commitment to apoptosis in LAMA cells (S2); Incomplete restoration of BCR-ABL signaling activity following washout of nilotinib, imatinib, or DCC-2036 tracks with intracellular drug retention and commitment to apoptosis in LAMA cells (S3); BCR-ABL signaling is partially attenuated in conditions of continuous low concentrations of ABL TKIs that induce apoptosis (S4); Commitment to apoptosis in primary CML cells tracks with intracellular retention of ABL TKIs (S5); Intracellular retention of dasatinib, nilotinib, and imatinib is reduced following washout in primary CML cells harboring the resistant BCR-ABLT315I mutant (S6).
Authors: Thomas O'Hare, Christopher A. Eide, Anupriya Agarwal, Lauren T. Adrian, Matthew S. Zabriskie, Ryan J. MacKenzie, Dorian H. LaTocha, Kara J. Johnson, Huihong You, Jenny Luo, Steven M. Riddle, Bryan D. Marks, Kurt W. Vogel, Dennis R. Koop, John Apgar, Jeffrey W. Tyner, Michael W. Deininger, Brian J. Druker
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361895457